EDX Medical Group plc (AQSE: EDX), a developer of digital diagnostic products for personalised cancer, heart disease and infectious disease treatments, announced on Wednesday that it has signed an exclusive distribution agreement with precision oncology company Curesponse Ltd to market the cResponse cancer assay in the UK, Sweden, Finland, Norway and Denmark.

cResponse is a cutting-edge platform that biologically evaluates how a patient's living tumour tissue responds to various medicines, identifying the most effective treatment options. It uniquely provides biological response data for chemotherapy, targeted biologics and immunotherapy drugs. This platform enables clinicians to quickly identify optimal treatments, potentially saving lives, reducing costs and speeding up drug discovery and development for pharmaceutical companies.

The cResponse platform generates a report ranking cancer drugs based on their predicted effect on an individual's tumour, with over 90% accuracy in clinical trials. It can be enhanced with rapid genomic sequencing to identify additional drug candidates. Powered by proprietary technologies and advanced AI algorithms, the platform has demonstrated its effectiveness through thousands of cancer tissue samples and hundreds of clinical cases in Israel and the UK. The cResponse test, conducted at a UKAS-accredited lab in London, has also earned a CE mark for Europe, confirming its regulatory approval and clinical readiness.

EDX Medical will commence commercial activities to support the clinical use of the cResponse assay in the UK and Nordics immediately, with plans to potentially expand the agreement with Curesponse.